{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "bad32605",
   "metadata": {},
   "source": [
    "# RAG Pipeline Exercise\n",
    "\n",
    "In this exercise you will build and **compare two simple Retrieval-Augmented Generation (RAG) pipelines**.\n",
    "\n",
    "You will work with a small collection of PDF documents (e.g. medical guidelines) and:\n",
    "\n",
    "1. Load and chunk the PDF documents.\n",
    "2. Create a vector index using **embedding model A** (local `BAAI/bge-m3`).\n",
    "3. Create a second index using **embedding model B** (e.g. OpenAI or Gemini embeddings).\n",
    "4. Implement a simple **retriever** and an **answering function** that calls an LLM with retrieved context.\n",
    "5. Automatically **generate questions** from the documents and use them to **compare two RAG configurations**.\n",
    "\n",
    "Cells marked with `# TODO` are **for students to implement**.\n",
    "Everything else is provided scaffolding."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4ddf82e6",
   "metadata": {},
   "source": [
    "## 0. Setup & Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "be93ec53",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "WARNING:tensorflow:From c:\\Users\\Phil\\AppData\\Local\\Programs\\Python\\Python313\\Lib\\site-packages\\tf_keras\\src\\losses.py:2976: The name tf.losses.sparse_softmax_cross_entropy is deprecated. Please use tf.compat.v1.losses.sparse_softmax_cross_entropy instead.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# TODO (easy): skim the imports and make sure you understand what each library is used for.\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "import os\n",
    "import glob\n",
    "from PyPDF2 import PdfReader\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "import faiss\n",
    "from sentence_transformers import SentenceTransformer\n",
    "import pickle\n",
    "import random\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "\n",
    "# LLM / API clients (we will mainly use OpenAI here; Gemini can be added as a bonus)\n",
    "from openai import OpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "68f16980",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load API keys from .env (you need to create this file once and add your keys)\n",
    "load_dotenv()\n",
    "\n",
    "deepinfra_key = os.getenv(\"DEEPINFRA_API_KEY\")\n",
    "openai_api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "google_api_key = os.getenv(\"GOOGLE_API_KEY\")\n",
    "anthropic_api_key = os.getenv(\"ANTHROPIC_API_KEY\")\n",
    "\n",
    "# For this exercise we mainly use OpenAI for both embeddings (RAG B) and chat completions.\n",
    "assert openai_api_key is not None, \"Please set OPENAI_API_KEY in your .env file.\"\n",
    "openai_client = OpenAI(api_key=openai_api_key)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "23ebcf52",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Make pandas show the full table and full cell content\n",
    "pd.set_option(\"display.max_rows\", None)       # show all rows\n",
    "pd.set_option(\"display.max_columns\", None)    # show all columns\n",
    "pd.set_option(\"display.max_colwidth\", None)   # don't truncate cell text"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fba2719d",
   "metadata": {},
   "source": [
    "## 1. Load PDF documents\n",
    "\n",
    "We assume there is a `data/` folder containing one or more PDF files.\n",
    "\n",
    "**Task:** implement `load_pdfs(glob_path)` so that it:\n",
    "- Iterates over all PDF files matching `glob_path`\n",
    "- Reads them with `PdfReader`\n",
    "- Concatenates the text of all pages into **one long string**."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "d8abcb21",
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_pdfs(glob_path: str = \"data/*.pdf\") -> str:\n",
    "    \"\"\"Load all PDFs matching the pattern and return their combined text.\n",
    "\n",
    "    TODO:\n",
    "    - Use `glob.glob(glob_path)` to iterate over file paths\n",
    "    - For each file, open it in binary mode and create a `PdfReader`\n",
    "    - Loop over `reader.pages` and extract text with the extract_text() function\n",
    "    - Concatenate everything into a single string `text`\n",
    "    - Be robust: skip pages where `extract_text()` returns None\n",
    "    \"\"\"\n",
    "    # YOUR CODE HERE\n",
    "    text = \"\"\n",
    "    for pdf_path in glob.glob(glob_path):\n",
    "        with open(pdf_path, \"rb\") as f:\n",
    "            reader = PdfReader(f)\n",
    "            for page in reader.pages:\n",
    "                page_text = page.extract_text()\n",
    "                if page_text:\n",
    "                    text += \" \" + page_text\n",
    "    return text\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "416c3ad0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of characters: 230708\n",
      "Preview:  Asthma: diagnosis, \n",
      "moni toring and chr onic \n",
      "asthma manag emen t (BTS, \n",
      "NICE, SI GN) \n",
      "NICE guideline \n",
      "Published: 27 No vember 202 4 \n",
      "www .nice.or g.uk/guidance/ng2 45 \n",
      "© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s). Your r esponsi bility \n",
      "The r ecommendations in t his guideline r epresent t he view of NICE, arriv ed at aft er car eful \n",
      "consideration of t he evidence a vailable. When e xercising t heir judg\n"
     ]
    }
   ],
   "source": [
    "# Run once and inspect\n",
    "raw_text = load_pdfs(\"data/*.pdf\")\n",
    "print(\"Number of characters:\", len(raw_text))\n",
    "print(\"Preview:\", raw_text[:500])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5c0c5a14",
   "metadata": {},
   "source": [
    "## 2. Chunk the text\n",
    "\n",
    "We will split the long text into overlapping chunks.\n",
    "\n",
    "Later you can **experiment** with different `chunk_size` and `chunk_overlap` to see how it affects retrieval.\n",
    "\n",
    "**Task:** start with the given parameters, run once, then try at least one alternative configuration and note the effects."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "a4e3f802",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RAG A: 130 chunks produced, first chunk length = 1995\n",
      "RAG B: 260 chunks produced, first chunk length = 979\n"
     ]
    }
   ],
   "source": [
    "# Base configuration (RAG A)\n",
    "chunk_size_a = 2000\n",
    "chunk_overlap_a = 200\n",
    "\n",
    "splitter_a = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=chunk_size_a,\n",
    "    chunk_overlap=chunk_overlap_a\n",
    ")\n",
    "\n",
    "chunks_a = splitter_a.split_text(raw_text)\n",
    "print(f\"RAG A: {len(chunks_a)} chunks produced, first chunk length = {len(chunks_a[0])}\")\n",
    "\n",
    "# TODO (mini-experiment): change chunk_size / chunk_overlap for RAG B and compare\n",
    "chunk_size_b = 1000   # e.g. smaller chunks\n",
    "chunk_overlap_b = 100\n",
    "\n",
    "splitter_b = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=chunk_size_b,\n",
    "    chunk_overlap=chunk_overlap_b\n",
    ")\n",
    "\n",
    "chunks_b = splitter_b.split_text(raw_text)\n",
    "print(f\"RAG B: {len(chunks_b)} chunks produced, first chunk length = {len(chunks_b[0])}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ec3511f4",
   "metadata": {},
   "source": [
    "## 3. Create embeddings and a FAISS index\n",
    "\n",
    "We start with **Embedding model A: `BAAI/bge-small-en`** using `sentence-transformers`.\n",
    "\n",
    "Then, as an optional extension, you can build **Embedding model B** using OpenAI or Gemini and compare.\n",
    "\n",
    "To keep the exercise manageable, the base version only **requires** BGE."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "b519161f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Embedding dimensionality (A): 384\n",
      "FAISS index (A) size: 130\n"
     ]
    }
   ],
   "source": [
    "# Embedding model A (local)\n",
    "model_name_a = \"BAAI/bge-small-en\"\n",
    "embedder_a = SentenceTransformer(model_name_a)\n",
    "\n",
    "# Compute embeddings for all chunks of configuration A\n",
    "embeddings_a = embedder_a.encode(chunks_a, convert_to_numpy=True)\n",
    "\n",
    "dimensions_a = embeddings_a.shape[1]\n",
    "print(\"Embedding dimensionality (A):\", dimensions_a)\n",
    "\n",
    "index_a = faiss.IndexFlatL2(dimensions_a)\n",
    "index_a.add(embeddings_a)\n",
    "print(\"FAISS index (A) size:\", index_a.ntotal)\n",
    "\n",
    "# Persist index/chunks if you like (optional)\n",
    "os.makedirs(\"faiss\", exist_ok=True)\n",
    "faiss.write_index(index_a, \"faiss/faiss_index_a.index\")\n",
    "with open(\"faiss/chunks_a.pkl\", \"wb\") as f:\n",
    "    pickle.dump(chunks_a, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "77271916",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "FAISS index (B) size: 260\n"
     ]
    }
   ],
   "source": [
    "# Embedding model B using OpenAI embeddings.\n",
    "\n",
    "# TODO:\n",
    "# - Use `openai_client.embeddings.create(...)` to compute embeddings for `chunks_b`\n",
    "# - Create a second FAISS index `index_b`\n",
    "# - Make sure to check the dimensionality from the first embedding vector\n",
    "\n",
    "# Example sketch (not complete, adapt & run if you have API access):\n",
    "# Initialize OpenAI client\n",
    "openai_client = OpenAI(api_key=openai_api_key)\n",
    "response = openai_client.embeddings.create(\n",
    "     model=\"text-embedding-3-small\",\n",
    "    input=chunks_b\n",
    ")\n",
    "embeddings_b = np.array([item.embedding for item in response.data])\n",
    "dim_b = embeddings_b.shape[1]\n",
    "index_b = faiss.IndexFlatL2(dim_b)\n",
    "index_b.add(embeddings_b)\n",
    "print(\"FAISS index (B) size:\", index_b.ntotal)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0339224e",
   "metadata": {},
   "source": [
    "## 4. Implement a simple retriever\n",
    "\n",
    "We now implement a generic retrieval function that:\n",
    "1. Embeds the query.\n",
    "2. Searches the FAISS index.\n",
    "3. Returns the corresponding text chunks.\n",
    "\n",
    "We implement it for configuration A. If you built configuration B, you can reuse the same function."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "aa6fbf82",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of retrieved chunks: 3\n",
      "Preview of first chunk: and signs of ot her causes of r espirat ory sympt oms but be awar e that e ven if \n",
      "examination r esult s are normal, t he person ma y still ha ve ast hma. [NICE 2017] \n",
      "Initial tr eatmen t and obje ctive tests f or acu te sym ptoms a t \n",
      "presen tation \n",
      "1.1.5 Treat people immediat ely if t hey are acut ely unw ell or highly sympt omatic at \n",
      "presentation, and per form objectiv e tests that ma y help s\n"
     ]
    }
   ],
   "source": [
    "def retrieve_texts(query: str, k: int, index, chunks, embedder) -> list:\n",
    "    \"\"\"Return the top-k most similar chunks for a query.\n",
    "\n",
    "    TODO (students):\n",
    "    - Encode the query with `embedder.encode(...)`\n",
    "    - Call `index.search(query_embedding, k)`\n",
    "    - Use the returned indices to select the chunks\n",
    "    - Return a list of strings (chunks)\n",
    "    \"\"\"\n",
    "    # YOUR CODE HERE\n",
    "    query_emb = embedder.encode([query], convert_to_numpy=True)\n",
    "    distances, indices = index.search(query_emb, k)\n",
    "    retrieved = [chunks[i] for i in indices[0]]\n",
    "    return retrieved\n",
    "\n",
    "# Quick sanity check\n",
    "test_query = \"What is the most important factor in diagnosing asthma?\"\n",
    "retrieved_text = retrieve_texts(test_query, k=3, index=index_a, chunks=chunks_a, embedder=embedder_a)\n",
    "print(\"Number of retrieved chunks:\", len(retrieved_text))\n",
    "print(\"Preview of first chunk:\", retrieved_text[0][:400])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "84287470",
   "metadata": {},
   "outputs": [],
   "source": [
    "def openai_embed_query(query: str) -> np.ndarray:\n",
    "    \"\"\"\n",
    "    Compute an OpenAI embedding for a single query string and\n",
    "    return it as a NumPy array of shape (1, dim).\n",
    "    \"\"\"\n",
    "    resp = openai_client.embeddings.create(\n",
    "        model=\"text-embedding-3-small\",\n",
    "        input=[query]  # list with one string\n",
    "    )\n",
    "    vec = np.array(resp.data[0].embedding, dtype=\"float32\")\n",
    "    return vec.reshape(1, -1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "68ab8b40",
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve_texts_b(query: str, k: int, index, chunks) -> list:\n",
    "    \"\"\"\n",
    "    Retrieve top-k chunks using OpenAI embeddings for the query.\n",
    "    \"\"\"\n",
    "    query_emb = openai_embed_query(query)  # shape (1, dim)\n",
    "    distances, indices = index.search(query_emb, k)\n",
    "    retrieved = [chunks[i] for i in indices[0]]\n",
    "    return retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f646fdc6",
   "metadata": {},
   "source": [
    "## 5. Implement `answer_query` using an LLM\n",
    "\n",
    "Now we build the actual RAG call:\n",
    "\n",
    "1. Use `retrieve_texts` to get top-`k` chunks.\n",
    "2. Concatenate them into a context string.\n",
    "3. Build a prompt that:\n",
    "   - shows the context\n",
    "   - asks the model to answer the user question based **only** on this context.\n",
    "4. Call the OpenAI chat completion API.\n",
    "\n",
    "This is the **core RAG function**."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "0d94610c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RAG answer: The most important factor in diagnosing asthma is a combination of a person's history suggestive of asthma, along with objective tests such as eosinophil count, fractional exhaled nitric oxide (FeNO) measurement, spirometry, or peak expiratory flow (PEF) assessments. However, it is noted that even if examination results are normal, a person may still have asthma.\n"
     ]
    }
   ],
   "source": [
    "def answer_query_a(query: str, k: int, index, chunks, embedder, client: OpenAI) -> str:\n",
    "    \"\"\"RAG-style answer: retrieve context and ask an LLM.\n",
    "\n",
    "    TODO (students):\n",
    "    - Use `retrieve_texts` to get `k` relevant chunks.\n",
    "    - Join them into a single context string.\n",
    "    - Build a chat prompt that instructs the model to answer *only* using the context.\n",
    "    - Call `client.chat.completions.create(...)` with model `\"gpt-4o-mini\"` (or similar).\n",
    "    - Return the model's answer text.\n",
    "    \"\"\"\n",
    "    retrieved_chunks = retrieve_texts(query, k, index, chunks, embedder)\n",
    "    context = \"\\n\\n---\\n\\n\".join(retrieved_chunks)\n",
    "\n",
    "    system_prompt = (\n",
    "        \"You are a helpful assistant answering questions based ONLY on the provided context. \"\n",
    "        \"If the answer is not in the context, say that you do not know.\"\n",
    "    )\n",
    "\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": system_prompt},\n",
    "        {\"role\": \"user\", \"content\": f\"Context:\\n{context}\\n\\nQuestion: {query}\"}\n",
    "    ]\n",
    "\n",
    "    completion = client.chat.completions.create(\n",
    "        model=\"gpt-4o-mini\",\n",
    "        messages=messages\n",
    "    )\n",
    "\n",
    "    return completion.choices[0].message.content.strip()\n",
    "\n",
    "# Quick manual test\n",
    "answer = answer_query_a(test_query, k=3, index=index_a, chunks=chunks_a, embedder=embedder_a, client=openai_client)\n",
    "print(\"RAG answer:\", answer)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4b13aade",
   "metadata": {},
   "source": [
    "### Answer Function with the other embedding type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "5994c414",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_query_b(query: str, k: int, index, chunks, client: OpenAI) -> str:\n",
    "    \"\"\"\n",
    "    RAG-style answer for configuration B (OpenAI embeddings + chunking B).\n",
    "    \"\"\"\n",
    "    retrieved_chunks = retrieve_texts_b(query, k, index, chunks)\n",
    "    context = \"\\n\\n---\\n\\n\".join(retrieved_chunks)\n",
    "\n",
    "    system_prompt = (\n",
    "        \"You are a helpful assistant answering questions based ONLY on the provided context. \"\n",
    "        \"If the answer is not in the context, say that you do not know.\"\n",
    "    )\n",
    "\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": system_prompt},\n",
    "        {\"role\": \"user\", \"content\": f\"Context:\\n{context}\\n\\nQuestion: {query}\"},\n",
    "    ]\n",
    "\n",
    "    completion = client.chat.completions.create(\n",
    "        model=\"gpt-4o-mini\",\n",
    "        messages=messages,\n",
    "    )\n",
    "\n",
    "    return completion.choices[0].message.content.strip()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7a86a92e",
   "metadata": {},
   "source": [
    "## 6. Generate questions from random chunks (automatic evaluation set)\n",
    "\n",
    "To compare two RAG configurations, we need **questions**.\n",
    "\n",
    "We will:\n",
    "- randomly sample a few chunks from the corpus,\n",
    "- ask an LLM to generate a **good question** whose answer is contained in the chunk.\n",
    "\n",
    "Then we can use these question–chunk pairs as a small evaluation set.\n",
    "\n",
    "We provide most of the implementation. Your job is mainly to:\n",
    "- inspect the code,\n",
    "- understand the prompt,\n",
    "- maybe tweak the number of chunks or retries."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "eb899fb6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Q1: How do the updated hypertension treatment recommendations prioritize individualized patient preferences and shared decision-making in the selection of step 2 and step 3 treatments?\n",
      "  From chunk preview: © NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#noti...\n",
      "\n",
      "Q2: How do the guidelines provided by NICE regarding asthma and hypertension management emphasize the importance of individualized care and the balance between following recommendations and considering patient-specific factors?\n",
      "  From chunk preview: BTS ISBN: 9 78-1-917 619-01-1 \n",
      "NICE ISBN: 9 78-1-47 31-6612- 7 \n",
      "SIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit o...\n",
      "\n",
      "Q3: What recommendations were made regarding the management of newly diagnosed asthma in individuals aged 12 and over, and how do different treatment options compare in terms of efficacy and cost-effectiveness?\n",
      "  From chunk preview: How the r ecommenda tion mig ht affect practice \n",
      "Digital inhalers ar e not r ecommended f or routine use in t he NHS, an...\n",
      "\n",
      "Q4: What steps should be taken if asthma control is inadequate after increasing MART treatment to a moderate dose, and how do the roles of FeNO and eosinophil levels influence the subsequent management plan?\n",
      "  From chunk preview: If treatment wit h MART using a lo w-dose maint enance r egimen does not pr ovide adequat e \n",
      "asthma contr ol, the commit...\n",
      "\n",
      "Q5: What factors should be considered when deciding to decrease maintenance therapy for asthma in patients whose condition has been well controlled?\n",
      "  From chunk preview: appr opriat e) the pot ential risks and benefit s of decr easing t heir maint enance \n",
      "therap y when t heir ast hma has b...\n",
      "\n"
     ]
    }
   ],
   "source": [
    "def generate_questions_for_random_chunks(chunks, num_chunks: int = 5, max_retries: int = 2):\n",
    "    selected_chunks = random.sample(chunks, num_chunks)\n",
    "    qa_pairs = []\n",
    "\n",
    "    for chunk in selected_chunks:\n",
    "        prompt = prompt = (\n",
    "            \"Based on the following text, generate an insightful question that covers its key content:\\n\\n\"\n",
    "            \"Text:\\n\" + chunk + \"\\n\\n\"\n",
    "            \"Question:\"\n",
    "        )\n",
    "\n",
    "        question = None\n",
    "        for attempt in range(max_retries):\n",
    "            try:\n",
    "                completion = openai_client.chat.completions.create(\n",
    "                    model=\"gpt-4o-mini\",\n",
    "                    messages=[{\"role\": \"user\", \"content\": prompt}]\n",
    "                )\n",
    "                question = completion.choices[0].message.content.strip()\n",
    "                if question:\n",
    "                    break\n",
    "            except Exception as e:\n",
    "                print(\"Error while generating question, retrying...\", e)\n",
    "\n",
    "        if question is None:\n",
    "            question = \"Error: could not generate question.\"\n",
    "\n",
    "        qa_pairs.append((chunk, question))\n",
    "\n",
    "    return qa_pairs\n",
    "\n",
    "questions = generate_questions_for_random_chunks(chunks_a, num_chunks=5, max_retries=2)\n",
    "for i, (chunk, q) in enumerate(questions, 1):\n",
    "    print(f\"Q{i}: {q}\\n  From chunk preview: {chunk[:120]}...\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3fd0eaf5",
   "metadata": {},
   "source": [
    "## 7. Compare two RAG configurations\n",
    "\n",
    "Now we can:\n",
    "- Use the generated questions,\n",
    "- Answer them with RAG configuration A (BGE + chunking A),\n",
    "- (Optional) Answer them with RAG configuration B (e.g. different chunking and/or different embeddings),\n",
    "- Compare the answers qualitatively.\n",
    "\n",
    "To keep the exercise manageable, we start with config A only.\n",
    "If you implemented config B, reuse `answer_query` with `index_b`, `chunks_b`, and your second embedder."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "a292474a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question: How do the updated hypertension treatment recommendations prioritize individualized patient preferences and shared decision-making in the selection of step 2 and step 3 treatments?\n",
      "Answer A: The updated hypertension treatment recommendations prioritize individualized patient preferences and shared decision-making in the selection of step 2 and step 3 treatments by emphasizing that the choice of drug should be discussed and agreed upon with the patient. This process takes into account the patient's step 1 treatment, the risks and benefits of each treatment option, and the patient's preferences and other clinical factors. Additionally, a NICE patient decision aid has been developed to support healthcare professionals and patients in discussing treatment options and making informed decisions together.\n",
      "Source chunk preview: © NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\n",
      "conditions#notice-of -right s).Page 43 of\n",
      "52  ...\n",
      "------------------------------------------------------------\n",
      "Question: How do the guidelines provided by NICE regarding asthma and hypertension management emphasize the importance of individualized care and the balance between following recommendations and considering patient-specific factors?\n",
      "Answer A: The guidelines provided by NICE for both asthma and hypertension management emphasize the importance of individualized care by stating that professionals and practitioners are expected to take the guidelines fully into account while also considering the individual needs, preferences, and values of their patients. It is noted that the recommendations are not mandatory and do not override the responsibility to make decisions that are appropriate to the circumstances of each individual, in consultation with them and their families or guardians. This balance highlights the necessity for healthcare providers to tailor their approach to the specific context of each patient's situation rather than solely relying on standardized recommendations.\n",
      "Source chunk preview: BTS ISBN: 9 78-1-917 619-01-1 \n",
      "NICE ISBN: 9 78-1-47 31-6612- 7 \n",
      "SIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma mana ...\n",
      "------------------------------------------------------------\n",
      "Question: What recommendations were made regarding the management of newly diagnosed asthma in individuals aged 12 and over, and how do different treatment options compare in terms of efficacy and cost-effectiveness?\n",
      "Answer A: The recommendations for the management of newly diagnosed asthma in individuals aged 12 and over include offering a low-dose inhaled corticosteroid (ICS)/formoterol combination inhaler to be taken as needed for symptom relief, referred to as as-needed AIR therapy. If the individual presents with highly symptomatic conditions or a severe exacerbation, treatment should start with low-dose maintenance and reliever therapy (MART), in addition to treating acute symptoms as necessary.\n",
      "\n",
      "In November 2024, only certain budesonide/formoterol inhalers were licensed for as-needed AIR therapy in mild asthma, while the use of other ICS/formoterol inhalers would be off-label. Evidence supporting the use of budesonide/formoterol is based on its use with a dry powder inhaler.\n",
      "\n",
      "The cost-effectiveness and efficacy of these treatment options can differ. Digital inhalers showed improvement in adherence to treatment; however, they did not result in significant improvement in asthma control measures and were associated with an unexplained increase in hospital admissions compared to usual care. Additionally, digital inhalers are more expensive than conventional devices. Hence, while digital inhalers could be valuable for select individuals (such as those considering biologic therapy), they are not recommended for routine use in the NHS due to cost-effectiveness concerns.\n",
      "\n",
      "Overall, the recommendations highlight a preference for low-dose ICS/formoterol combination inhalers as initial treatment and emphasize the need for further research to identify scenarios where more expensive options like digital inhalers may be justified.\n",
      "Source chunk preview: How the r ecommenda tion mig ht affect practice \n",
      "Digital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \n",
      "curr ...\n",
      "------------------------------------------------------------\n",
      "Question: What steps should be taken if asthma control is inadequate after increasing MART treatment to a moderate dose, and how do the roles of FeNO and eosinophil levels influence the subsequent management plan?\n",
      "Answer A: If asthma control is inadequate after increasing MART treatment to a moderate dose, the following steps should be taken:\n",
      "\n",
      "1. Check both FeNO and eosinophil levels.\n",
      "2. Assess adherence to the prescribed treatment.\n",
      "\n",
      "- If either FeNO or eosinophil count is raised despite good adherence, this indicates a relatively high risk of adverse outcomes, and a referral to an asthma specialist for further assessment and management is appropriate.\n",
      "- If control is inadequate but neither FeNO nor eosinophil count is raised, the possible options for management include the addition of either a leukotriene receptor antagonist (LTRA) or a long-acting muscarinic receptor antagonist (LAMA).\n",
      "Source chunk preview: If treatment wit h MART using a lo w-dose maint enance r egimen does not pr ovide adequat e \n",
      "asthma contr ol, the committ ee agr eed t hat incr easing ...\n",
      "------------------------------------------------------------\n",
      "Question: What factors should be considered when deciding to decrease maintenance therapy for asthma in patients whose condition has been well controlled?\n",
      "Answer A: I do not know.\n",
      "Source chunk preview: appr opriat e) the pot ential risks and benefit s of decr easing t heir maint enance \n",
      "therap y when t heir ast hma has been w ell contr olled on t hei ...\n",
      "------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "def answer_generated_questions_a(question_tuples, k, index, chunks, embedder, client):\n",
    "    results = []\n",
    "    for chunk, question in question_tuples:\n",
    "        answer = answer_query_a(question, k, index, chunks, embedder, client)\n",
    "        results.append({\n",
    "            \"chunk\": chunk,\n",
    "            \"question\": question,\n",
    "            \"answer\": answer\n",
    "        })\n",
    "    return results\n",
    "\n",
    "results_a = answer_generated_questions_a(\n",
    "    questions,\n",
    "    k=5,\n",
    "    index=index_a,\n",
    "    chunks=chunks_a,\n",
    "    embedder=embedder_a,\n",
    "    client=openai_client,\n",
    ")\n",
    "\n",
    "for item in results_a:\n",
    "    print(\"Question:\", item[\"question\"])\n",
    "    print(\"Answer A:\", item[\"answer\"])\n",
    "    print(\"Source chunk preview:\", item[\"chunk\"][:150], \"...\")\n",
    "    print(\"-\" * 60)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2ec212b7",
   "metadata": {},
   "source": [
    "### Extension: add RAG B and create a comparison table\n",
    "\n",
    "If you implemented a second configuration (e.g. different chunking + OpenAI embeddings):\n",
    "\n",
    "1. Build `index_b` using OpenAI embeddings and `chunks_b`.\n",
    "2. Implement `openai_embed_query`, `retrieve_texts_b`, and `answer_query_b`.\n",
    "3. Run `results_b = answer_generated_questions_b(questions, k=5, index=index_b, chunks=chunks_b, client=openai_client)`.\n",
    "4. For each question, compare:\n",
    "   - Which answer is more complete / specific?\n",
    "   - Which one is better grounded in the source chunk?\n",
    "5. Summarise your findings in a short **markdown cell** or a small table.\n",
    "\n",
    "---\n",
    "\n",
    "This concludes the core RAG exercise.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "faa74961",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_generated_questions_b(question_tuples, k, index, chunks, client):\n",
    "    \"\"\"\n",
    "    Use RAG B to answer a list of (chunk, question) pairs.\n",
    "    \"\"\"\n",
    "    results = []\n",
    "    for chunk, question in question_tuples:\n",
    "        answer = answer_query_b(question, k, index, chunks, client)\n",
    "        results.append({\n",
    "            \"chunk\": chunk,\n",
    "            \"question\": question,\n",
    "            \"answer\": answer,\n",
    "        })\n",
    "    return results\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "e9ee1310",
   "metadata": {},
   "outputs": [],
   "source": [
    "results_b = answer_generated_questions_b(\n",
    "    questions,\n",
    "    k=5,\n",
    "    index=index_b,\n",
    "    chunks=chunks_b,\n",
    "    client=openai_client,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "bc18c46e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Answer A (BGE + config A)</th>\n",
       "      <th>Answer B (OpenAI + config B)</th>\n",
       "      <th>Source chunk (A) preview</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>How do the updated hypertension treatment recommendations prioritize individualized patient preferences and shared decision-making in the selection of step 2 and step 3 treatments?</td>\n",
       "      <td>The updated hypertension treatment recommendations prioritize individualized patient preferences and shared decision-making in the selection of step 2 and step 3 treatments by emphasizing that the choice of drug should be discussed and agreed upon with the patient. This process takes into account the patient's step 1 treatment, the risks and benefits of each treatment option, and the patient's preferences and other clinical factors. Additionally, a NICE patient decision aid has been developed to support healthcare professionals and patients in discussing treatment options and making informed decisions together.</td>\n",
       "      <td>The updated hypertension treatment recommendations emphasize a personalized approach by advocating for the discussion of treatment options based on the individual's step 1 treatment, as well as the risks and benefits associated with each treatment. The committee members agreed that treatment choices should be made collaboratively with the patient, taking into account their preferences and individual risk factors, particularly in light of the patient's cardiovascular disease risk. This approach is supported by NICE's patient decision aid, which aims to facilitate discussions between healthcare professionals and patients about different treatment options, ensuring that decisions are tailored to the specific needs and circumstances of each individual.</td>\n",
       "      <td>© NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\\nconditions#notice-of -right s).Page 43 of\\n52 available on drug tr eatment s for hyper tension w...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>How do the guidelines provided by NICE regarding asthma and hypertension management emphasize the importance of individualized care and the balance between following recommendations and considering patient-specific factors?</td>\n",
       "      <td>The guidelines provided by NICE for both asthma and hypertension management emphasize the importance of individualized care by stating that professionals and practitioners are expected to take the guidelines fully into account while also considering the individual needs, preferences, and values of their patients. It is noted that the recommendations are not mandatory and do not override the responsibility to make decisions that are appropriate to the circumstances of each individual, in consultation with them and their families or guardians. This balance highlights the necessity for healthcare providers to tailor their approach to the specific context of each patient's situation rather than solely relying on standardized recommendations.</td>\n",
       "      <td>The guidelines provided by NICE for asthma and hypertension management emphasize the importance of individualized care by stating that professionals and practitioners are expected to take the guideline fully into account alongside the individual needs, preferences, and values of their patients. It is specifically noted that it is not mandatory to apply the recommendations and that the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardians. This highlights the need for a balanced approach where the recommendations serve as guidance, but the specific clinical context and patient preferences are paramount in decision-making.</td>\n",
       "      <td>BTS ISBN: 9 78-1-917 619-01-1 \\nNICE ISBN: 9 78-1-47 31-6612- 7 \\nSIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\\n(NG2 45)\\n© NICE 202 4. Al...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>What recommendations were made regarding the management of newly diagnosed asthma in individuals aged 12 and over, and how do different treatment options compare in terms of efficacy and cost-effectiveness?</td>\n",
       "      <td>The recommendations for the management of newly diagnosed asthma in individuals aged 12 and over include offering a low-dose inhaled corticosteroid (ICS)/formoterol combination inhaler to be taken as needed for symptom relief, referred to as as-needed AIR therapy. If the individual presents with highly symptomatic conditions or a severe exacerbation, treatment should start with low-dose maintenance and reliever therapy (MART), in addition to treating acute symptoms as necessary.\\n\\nIn November 2024, only certain budesonide/formoterol inhalers were licensed for as-needed AIR therapy in mild asthma, while the use of other ICS/formoterol inhalers would be off-label. Evidence supporting the use of budesonide/formoterol is based on its use with a dry powder inhaler.\\n\\nThe cost-effectiveness and efficacy of these treatment options can differ. Digital inhalers showed improvement in adherence to treatment; however, they did not result in significant improvement in asthma control measures and were associated with an unexplained increase in hospital admissions compared to usual care. Additionally, digital inhalers are more expensive than conventional devices. Hence, while digital inhalers could be valuable for select individuals (such as those considering biologic therapy), they are not recommended for routine use in the NHS due to cost-effectiveness concerns.\\n\\nOverall, the recommendations highlight a preference for low-dose ICS/formoterol combination inhalers as initial treatment and emphasize the need for further research to identify scenarios where more expensive options like digital inhalers may be justified.</td>\n",
       "      <td>The recommendations for the management of newly diagnosed asthma in individuals aged 12 and over include:\\n\\n1. **Offer a low-dose inhaled corticosteroid (ICS)/formoterol combination inhaler** to be taken as needed for symptom relief (as-needed AIR therapy) to people aged 12 and over with newly diagnosed asthma.\\n\\n2. If a person presents highly symptomatic (for example, with regular nocturnal waking) or has a severe exacerbation, start treatment with a low-dose maintenance and reliever therapy (MART) regimen.\\n\\nIn terms of efficacy and cost-effectiveness:\\n\\n- The use of combination inhalers represents a significant change in practice compared to current treatments, which often involve either a short-acting beta-agonist (SABA) alone or with regular ICS plus SABA as needed. \\n\\n- Combination inhalers are more expensive than using a SABA alone but cheaper than the combination of regular ICS plus SABA as needed. \\n\\n- There are anticipated future savings due to a reduction in severe asthma exacerbations compared to the existing treatment options. \\n\\nThe recommendations indicate a shift towards using a combination inhaler more regularly, with an emphasis on better management of symptoms and prevention of exacerbations.</td>\n",
       "      <td>How the r ecommenda tion mig ht affect practice \\nDigital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \\ncurrent practice. \\nReturn t o recommendations \\nMedicin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>What steps should be taken if asthma control is inadequate after increasing MART treatment to a moderate dose, and how do the roles of FeNO and eosinophil levels influence the subsequent management plan?</td>\n",
       "      <td>If asthma control is inadequate after increasing MART treatment to a moderate dose, the following steps should be taken:\\n\\n1. Check both FeNO and eosinophil levels.\\n2. Assess adherence to the prescribed treatment.\\n\\n- If either FeNO or eosinophil count is raised despite good adherence, this indicates a relatively high risk of adverse outcomes, and a referral to an asthma specialist for further assessment and management is appropriate.\\n- If control is inadequate but neither FeNO nor eosinophil count is raised, the possible options for management include the addition of either a leukotriene receptor antagonist (LTRA) or a long-acting muscarinic receptor antagonist (LAMA).</td>\n",
       "      <td>If asthma control is inadequate after increasing MART treatment to a moderate dose, the following steps should be taken:\\n\\n1. Check the fractional exhaled nitric oxide (FeNO) level and the blood eosinophil count.\\n2. If either the FeNO or eosinophil count is raised, refer the patient to a specialist in asthma care.\\n3. If neither FeNO nor eosinophil count is raised, consider a trial of either a leukotriene receptor antagonist (LTRA) or a long-acting muscarinic receptor antagonist (LAMA) in addition to moderate-dose MART. This treatment should be given for a trial period of 8 to 12 weeks unless side effects occur.\\n\\nAt the end of the trial:\\n- If asthma is controlled, continue the treatment.\\n- If control has improved but is still inadequate, continue the treatment and start a trial of the other medicine (either LTRA or LAMA).</td>\n",
       "      <td>If treatment wit h MART using a lo w-dose maint enance r egimen does not pr ovide adequat e \\nasthma contr ol, the committ ee agr eed t hat incr easing t he maint enance element of MART \\nto moderat e d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>What factors should be considered when deciding to decrease maintenance therapy for asthma in patients whose condition has been well controlled?</td>\n",
       "      <td>I do not know.</td>\n",
       "      <td>When considering a decrease in maintenance therapy for asthma in patients whose condition has been well controlled, the following factors should be considered:\\n\\n1. Clinical effectiveness of the current treatment.\\n2. Side effects experienced by the patient.\\n3. The patient's preference and agreement regarding the decrease in therapy.\\n4. Monitoring and review mechanisms for the effects of decreasing therapy, including self-monitoring and healthcare professional follow-up.\\n5. Review and update of the patient's asthma action plan when decreasing maintenance therapy.\\n\\nIt is also recommended to allow at least 8 to 12 weeks before considering further treatment reduction.</td>\n",
       "      <td>appr opriat e) the pot ential risks and benefit s of decr easing t heir maint enance \\ntherap y when t heir ast hma has been w ell contr olled on t heir curr ent maint enance \\ntherap y. [NICE 2017 , BT...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                          Question  \\\n",
       "0                                             How do the updated hypertension treatment recommendations prioritize individualized patient preferences and shared decision-making in the selection of step 2 and step 3 treatments?   \n",
       "1  How do the guidelines provided by NICE regarding asthma and hypertension management emphasize the importance of individualized care and the balance between following recommendations and considering patient-specific factors?   \n",
       "2                   What recommendations were made regarding the management of newly diagnosed asthma in individuals aged 12 and over, and how do different treatment options compare in terms of efficacy and cost-effectiveness?   \n",
       "3                      What steps should be taken if asthma control is inadequate after increasing MART treatment to a moderate dose, and how do the roles of FeNO and eosinophil levels influence the subsequent management plan?   \n",
       "4                                                                                 What factors should be considered when deciding to decrease maintenance therapy for asthma in patients whose condition has been well controlled?   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Answer A (BGE + config A)  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         The updated hypertension treatment recommendations prioritize individualized patient preferences and shared decision-making in the selection of step 2 and step 3 treatments by emphasizing that the choice of drug should be discussed and agreed upon with the patient. This process takes into account the patient's step 1 treatment, the risks and benefits of each treatment option, and the patient's preferences and other clinical factors. Additionally, a NICE patient decision aid has been developed to support healthcare professionals and patients in discussing treatment options and making informed decisions together.   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The guidelines provided by NICE for both asthma and hypertension management emphasize the importance of individualized care by stating that professionals and practitioners are expected to take the guidelines fully into account while also considering the individual needs, preferences, and values of their patients. It is noted that the recommendations are not mandatory and do not override the responsibility to make decisions that are appropriate to the circumstances of each individual, in consultation with them and their families or guardians. This balance highlights the necessity for healthcare providers to tailor their approach to the specific context of each patient's situation rather than solely relying on standardized recommendations.   \n",
       "2  The recommendations for the management of newly diagnosed asthma in individuals aged 12 and over include offering a low-dose inhaled corticosteroid (ICS)/formoterol combination inhaler to be taken as needed for symptom relief, referred to as as-needed AIR therapy. If the individual presents with highly symptomatic conditions or a severe exacerbation, treatment should start with low-dose maintenance and reliever therapy (MART), in addition to treating acute symptoms as necessary.\\n\\nIn November 2024, only certain budesonide/formoterol inhalers were licensed for as-needed AIR therapy in mild asthma, while the use of other ICS/formoterol inhalers would be off-label. Evidence supporting the use of budesonide/formoterol is based on its use with a dry powder inhaler.\\n\\nThe cost-effectiveness and efficacy of these treatment options can differ. Digital inhalers showed improvement in adherence to treatment; however, they did not result in significant improvement in asthma control measures and were associated with an unexplained increase in hospital admissions compared to usual care. Additionally, digital inhalers are more expensive than conventional devices. Hence, while digital inhalers could be valuable for select individuals (such as those considering biologic therapy), they are not recommended for routine use in the NHS due to cost-effectiveness concerns.\\n\\nOverall, the recommendations highlight a preference for low-dose ICS/formoterol combination inhalers as initial treatment and emphasize the need for further research to identify scenarios where more expensive options like digital inhalers may be justified.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         If asthma control is inadequate after increasing MART treatment to a moderate dose, the following steps should be taken:\\n\\n1. Check both FeNO and eosinophil levels.\\n2. Assess adherence to the prescribed treatment.\\n\\n- If either FeNO or eosinophil count is raised despite good adherence, this indicates a relatively high risk of adverse outcomes, and a referral to an asthma specialist for further assessment and management is appropriate.\\n- If control is inadequate but neither FeNO nor eosinophil count is raised, the possible options for management include the addition of either a leukotriene receptor antagonist (LTRA) or a long-acting muscarinic receptor antagonist (LAMA).   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     I do not know.   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Answer B (OpenAI + config B)  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The updated hypertension treatment recommendations emphasize a personalized approach by advocating for the discussion of treatment options based on the individual's step 1 treatment, as well as the risks and benefits associated with each treatment. The committee members agreed that treatment choices should be made collaboratively with the patient, taking into account their preferences and individual risk factors, particularly in light of the patient's cardiovascular disease risk. This approach is supported by NICE's patient decision aid, which aims to facilitate discussions between healthcare professionals and patients about different treatment options, ensuring that decisions are tailored to the specific needs and circumstances of each individual.   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               The guidelines provided by NICE for asthma and hypertension management emphasize the importance of individualized care by stating that professionals and practitioners are expected to take the guideline fully into account alongside the individual needs, preferences, and values of their patients. It is specifically noted that it is not mandatory to apply the recommendations and that the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardians. This highlights the need for a balanced approach where the recommendations serve as guidance, but the specific clinical context and patient preferences are paramount in decision-making.   \n",
       "2  The recommendations for the management of newly diagnosed asthma in individuals aged 12 and over include:\\n\\n1. **Offer a low-dose inhaled corticosteroid (ICS)/formoterol combination inhaler** to be taken as needed for symptom relief (as-needed AIR therapy) to people aged 12 and over with newly diagnosed asthma.\\n\\n2. If a person presents highly symptomatic (for example, with regular nocturnal waking) or has a severe exacerbation, start treatment with a low-dose maintenance and reliever therapy (MART) regimen.\\n\\nIn terms of efficacy and cost-effectiveness:\\n\\n- The use of combination inhalers represents a significant change in practice compared to current treatments, which often involve either a short-acting beta-agonist (SABA) alone or with regular ICS plus SABA as needed. \\n\\n- Combination inhalers are more expensive than using a SABA alone but cheaper than the combination of regular ICS plus SABA as needed. \\n\\n- There are anticipated future savings due to a reduction in severe asthma exacerbations compared to the existing treatment options. \\n\\nThe recommendations indicate a shift towards using a combination inhaler more regularly, with an emphasis on better management of symptoms and prevention of exacerbations.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                If asthma control is inadequate after increasing MART treatment to a moderate dose, the following steps should be taken:\\n\\n1. Check the fractional exhaled nitric oxide (FeNO) level and the blood eosinophil count.\\n2. If either the FeNO or eosinophil count is raised, refer the patient to a specialist in asthma care.\\n3. If neither FeNO nor eosinophil count is raised, consider a trial of either a leukotriene receptor antagonist (LTRA) or a long-acting muscarinic receptor antagonist (LAMA) in addition to moderate-dose MART. This treatment should be given for a trial period of 8 to 12 weeks unless side effects occur.\\n\\nAt the end of the trial:\\n- If asthma is controlled, continue the treatment.\\n- If control has improved but is still inadequate, continue the treatment and start a trial of the other medicine (either LTRA or LAMA).   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                When considering a decrease in maintenance therapy for asthma in patients whose condition has been well controlled, the following factors should be considered:\\n\\n1. Clinical effectiveness of the current treatment.\\n2. Side effects experienced by the patient.\\n3. The patient's preference and agreement regarding the decrease in therapy.\\n4. Monitoring and review mechanisms for the effects of decreasing therapy, including self-monitoring and healthcare professional follow-up.\\n5. Review and update of the patient's asthma action plan when decreasing maintenance therapy.\\n\\nIt is also recommended to allow at least 8 to 12 weeks before considering further treatment reduction.   \n",
       "\n",
       "                                                                                                                                                                                          Source chunk (A) preview  \n",
       "0    © NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\\nconditions#notice-of -right s).Page 43 of\\n52 available on drug tr eatment s for hyper tension w...  \n",
       "1  BTS ISBN: 9 78-1-917 619-01-1 \\nNICE ISBN: 9 78-1-47 31-6612- 7 \\nSIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\\n(NG2 45)\\n© NICE 202 4. Al...  \n",
       "2  How the r ecommenda tion mig ht affect practice \\nDigital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \\ncurrent practice. \\nReturn t o recommendations \\nMedicin...  \n",
       "3    If treatment wit h MART using a lo w-dose maint enance r egimen does not pr ovide adequat e \\nasthma contr ol, the committ ee agr eed t hat incr easing t he maint enance element of MART \\nto moderat e d...  \n",
       "4    appr opriat e) the pot ential risks and benefit s of decr easing t heir maint enance \\ntherap y when t heir ast hma has been w ell contr olled on t heir curr ent maint enance \\ntherap y. [NICE 2017 , BT...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "rows = []\n",
    "\n",
    "for qa_a, qa_b in zip(results_a, results_b):\n",
    "    rows.append({\n",
    "        \"Question\": qa_a[\"question\"],\n",
    "        \"Answer A (BGE + config A)\": qa_a[\"answer\"],\n",
    "        \"Answer B (OpenAI + config B)\": qa_b[\"answer\"],\n",
    "        \"Source chunk (A) preview\": qa_a[\"chunk\"][:200] + \"...\"\n",
    "    })\n",
    "\n",
    "df_comparison = pd.DataFrame(rows)\n",
    "display(df_comparison)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d06db215",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
